SOMERSET, N.J.–(BUSINESS WIRE)–Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that current board member and lead independent director J. Martin (“Marty”) Carroll has been unanimously selected by its Board of Directors to succeed John Chiminski and serve as Chair following Mr. Chiminski’s retirement.
Mr. Chiminski, who led Catalent for more than 13 years as CEO and was succeeded by Alessandro Maselli on July 1, 2022, will retire from his remaining responsibilities on June 30, 2023, upon completion of his transitional year as Executive Chair of Catalent’s Board of Directors. Director Rolf Classon will also retire from the Board as of the Company’s next annual meeting in October 2023, having reached the Board’s mandatory retirement age, and Director Peter Zippelius, the designee of investors affiliated with Leonard Green & Partners pursuant to a Stockholders’ Agreement with the Company, will retire from the Board at the end of January 2023 in accordance with the terms of that agreement, since those investors no longer own the minimum threshold required for designating a director.
“On behalf of the Catalent Board of Directors and the entire company, I want to thank John for his leadership and countless contributions to our mission to help people live better and healthier lives,” said Mr. Carroll. “John’s vision for, and passionate leadership of, Catalent helped advance our strategy, achieving unprecedented performance, growth, and value-creation, while positioning our company as a leading player in the CDMO industry.”
“The Board would also like to thank Rolf and Pete for their service,” added Mr. Carroll. “Rolf was a highly valued member of our board for the last eight years, and his guidance and deep industry insights have proven invaluable to Catalent’s leadership and his fellow board members. Few healthcare sector leaders have the depth and breadth of experience that Rolf possesses. Pete has also been a valuable Board member, serving during a period when Catalent’s biologics assets have undergone substantial growth and change, creating a true leader in the field.”
“It has been an honor to serve Catalent both operationally and at the Board level for so many years, and I am immensely proud of our many accomplishments during that time,” said Mr. Chiminski. “I thank all of our Catalent colleagues for their tireless dedication and commitment to putting patients first, and I look forward to supporting Marty and the Board with a smooth transition, while following the company’s continued success well into the future.”
“I’ve been privileged to serve on Catalent’s board during this time of extraordinary growth and through the challenges of the global pandemic,” said Mr. Classon. “It has been deeply rewarding to work alongside such a diverse, talented board and serve a company that positively impacts the lives of millions of patients around the world.”
Mr. Zippelius said, “I am grateful to have had the opportunity to serve on the Catalent Board of Directors and that the Leonard Green team helped make possible a significant expansion of Catalent’s capabilities. Catalent has built an extraordinary business and continues to have significant opportunities in front of it.”
Mr. Carroll added, “I appreciate our board’s confidence in me, and I am excited to continue working with Alessandro, the leadership team, and our directors to further optimize our core businesses and continue to build a uniquely positioned platform for long-term growth and value-creation. These changes represent Catalent’s commitment to ongoing board refreshment, and I am confident that the company has the right teams in place to execute on our strategic objectives while enhancing value for our shareholders.”
Following the retirements of Messrs. Chiminski, Classon, and Zippelius, the Board will be reduced to 11 directors, including 9 independent members, 3 female members, and 2 ethnically or racially diverse members.
About Marty Carroll
Mr. Carroll has served on Catalent’s board since July 2015 and has been its lead independent director since October 2021. Before that, he served as president and CEO of Boehringer Ingelheim Corporation and of Boehringer Pharmaceuticals, Inc. from 2003 until 2011 and as head, corporate strategy and development of Boehringer Ingelheim GmbH from 2012 until his retirement in 2013. In addition, he served as a director of Boehringer Ingelheim Corporation from 2003 until December 2012. Prior to that, Mr. Carroll worked at Merck & Company, Inc. for over 25 years. Mr. Carroll has been chairperson of the board of directors of Esperion Therapeutics since June 2022. He has also served as a director of numerous other life sciences companies, including: Durata Therapeutics, Inc., Vivus, Inc., Therapeutics MD, Mallinckrodt plc, and Inotek.
About Catalent
Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply around 80 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of approximately 18,000 includes more than 3,000 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated nearly $5 billion in revenue in its 2022 fiscal year. For more information, visit www.catalent.com.
